S&P 500
Nasdaq
Dow Jones
NVDA
AAPL
TSLA
MSFT
BTC-USD
15-min delayed
Live
Home Market News Price Targets Penny Stocks Crypto Economy Commodities Education
Stocks About Contact

Gilead Sciences Inc

GILD XNAS
$131.33 -2.73 (-2.04%) ▼ 15-min delayed
Open
$130.00
High
$133.34
Low
$129.00
Volume
10.25M
Market Cap
$163.06B

About Gilead Sciences Inc

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 17.0K Website →

Key Financials

Period Revenue Net Income EPS
Q1 2026 $6.96B $2.02B $1.63
FY 2025 $29.44B $8.51B $6.84
Q3 2025 $7.77B $3.05B $2.46
Q2 2025 $7.08B $1.96B $1.57

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026
Calendar →

Get GILD Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Gilead Sciences Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.